At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 27 enrolled
Drug / intervention
Apixaban 5 MG Oral Tablet [ELIQUIS] +1 moredrug
Likely dose
Apixaban 5 MG Oral Tablet [ELIQUIS]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus
In Brief
A Phase 3 clinical trial evaluating Apixaban 5 MG Oral Tablet [ELIQUIS] and Warfarin Sodium for Left Ventricular Thrombosis. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the novel oral anticoagulant apixaban with the standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus over 3 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeft Ventricular Thrombosis
CountriesMalaysia
CollaboratorsInstitut Jantung Negara
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedDec 5, 2016
Enrollment StartNov 1, 2016
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.6 years ago
Interventions
Apixaban 5 MG Oral Tablet [ELIQUIS]drug
Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
Warfarin Sodiumdrug
as controlled arm since warfarin is the standard therapy for LV thrombus